Corporate Snapshot

Generex Biotechnology Corporation ("Generex" or "the Company") is a specialty pharmaceutical company focused on developing drug delivery systems and technologies to treat cancers, allergies, and autoimmune and infectious diseases. Generex's primary platform technology, RapidMist™, is a device and liquid formulation combination that delivers macromolecule drugs (e.g., insulin) into the bloodstream via the inner lining of the mouth (the buccal mucosa). The Company's lead product, Generex Oral-lyn®, is a buccal insulin spray that uses the RapidMist™ platform to treat Type 1 and Type 2 diabetes. Having demonstrated safety and efficacy in clinical trials to date, Generex Oral-lyn® is approved for sale in Ecuador, India, Lebanon, and Algeria. A global Phase III clinical trial with Generex Oral-lyn® is ongoing in preparation for North American and European registration. Generex's wholly owned subsidiary, Antigen Express, Inc., develops immunotherapeutic vaccine candidates using proprietary platform technologies that modulate the immune system to elicit specific responses.

* The Corporate Snapshot was last updated on March 9, 2010.

Latest Research

Executive
Informational
Overview

2009-10-26

Click to View

* An earlier Executive Informational Overview was published on August 20, 2008. A copy of this report can be obtained by emailing eio@crystalra.com.

Stock Information (GNBT-OTC)